CBLL
CeriBell, Inc
NASDAQ: CBLL · HEALTHCARE · MEDICAL DEVICES
$20.16
+4.73% today
Updated 2026-04-30
Market cap
$802.14M
P/E ratio
—
P/S ratio
9.01x
EPS (TTM)
$-1.46
Dividend yield
—
52W range
$11 – $24
Volume
0.3M
CeriBell, Inc (CBLL) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
4 of 7
Last 7 quarters
Avg EPS surprise
+56.8%
Last 4 quarters
Revenue YoY growth
+33.7%
Most recent quarter
EPS YoY growth
+10.0%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+0.9%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+3.9%
2025-11-04
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-03 | $-0.36 | +12.2% | $18.16 | $17.77 | -2.1% |
| 2025-11-04 | $0.37 | +189.4% | $11.34 | $11.78 | +3.9% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.41 | $-0.36 | +12.2% | $24.78M | +33.7% |
| 2025-09-30 | $-0.41 | $0.37 | +189.4% | $22.59M | +31.4% |
| 2025-06-30 | $-0.40 | $-0.38 | +4.6% | $21.20M | +42.7% |
| 2025-03-31 | $-0.46 | $-0.36 | +21.2% | $20.49M | — |
| 2024-12-31 | $-0.31 | $-0.40 | -27.5% | $18.53M | — |
| 2024-09-30 | $-0.87 | $-1.85 | -113.2% | $17.20M | — |
| 2024-06-30 | $0.00 | $-0.37 | — | $14.86M | — |
Frequently asked questions
Has CeriBell, Inc beaten earnings estimates?
CeriBell, Inc has beaten Wall Street EPS estimates in 4 of its last 7 quarterly reports, with an average EPS surprise of +56.8% over the last 4 quarters.
How does CBLL stock react to earnings?
CBLL stock has moved an average of +0.9% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is CeriBell, Inc's revenue growth rate?
CeriBell, Inc reported year-over-year revenue growth of +33.7% in its most recent quarter, with EPS growing +10.0% year-over-year.